Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis – usefulness of alendronate and risedronate

Author： Iwamoto Jun Takeda Tsuyoshi Sato Yoshihiro

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.8, Iss.16, 2007-11, pp. : 2743-2756

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Quercetin prevents experimental glucocorticoid-induced osteoporosis: a comparative study with alendronate

By Djalali Mahmoud

Canadian Journal of Physiology and Pharmacology, Vol. 91, Iss. 5, 2013-01 ,pp. : 380-385

NRC Research Press

Access to resources Recommend Favorite

Prevention of glucocorticoid-induced osteoporosis

By van Brussel MS Bultink IEM Lems WF

Expert Opinion on Pharmacotherapy, Vol. 10, Iss. 6, 2009-04 ,pp. : 997-1005

Informa Healthcare

Access to resources Recommend Favorite

Pathogenesis and Treatment of Glucocorticoid-Induced Osteoporosis

By Rackoff P.J.

Drugs & Aging, Vol. 12, Iss. 6, 1998-06 ,pp. : 477-484

Adis International

Access to resources Recommend Favorite

Therapeutic patenting for glucocorticoid-induced osteoporosis

By Cooper M.S. Stewart P.M.

Expert Opinion on Therapeutic Patents, Vol. 10, Iss. 6, 2000-06 ,pp. : 847-857

Informa Healthcare

Access to resources Recommend Favorite

Antifracture Efficacy of Currently Available Therapies for Postmenopausal Osteoporosis

By Reginster Jean-Yves

Drugs, Vol. 71, Iss. 1, 2011-01 ,pp. : 65-78

Adis International

Access to resources Recommend Favorite